Immunological alterations and neuropsychiatry symptoms: antimicroglia antibodies and psychopathological subgroups in Alzheimer’s Disease
Various immune mechanisms seem to accompany the degenerative process in Alzheimer’s disease (AD) and may contribute to the destruction of brain tissue. Acute phase proteins are components of the amyloid of senile plaques and may influence the degradation of amyloid precursor protein into amyloid beta protein (Bauer etal., 1991). Elevation of various cytokines in sera and brain tissue of AD patients and activation of the complement cascade have been demonstrated (Bauer et al., 1992; Aisen and Davis, 1994). Several studies with anti-inflammatory drugs have been reported. However, results are preliminary and not yet conclusive.
KeywordsMicroglial Cell Immunological Alteration Motor Restlessness Neurotic Disorder Amoeboid Microglial Cell
Unable to display preview. Download preview PDF.
- American Psychiatric Association (1994) Diagnostic and statistical manual, 4th edn (DSM-IV). APA, Washington DCGoogle Scholar
- Folstein MF, Folstein SE, McHugh PR (1975) “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198Google Scholar
- Henneberg AE, Yueksektepeli B. Bauer M (1993b) Brain antibodies in sera of patients suffering from schizophrenia or schizoaffective diseases, but not from neurotic disorders: the phenomenon is independent from medication. Immunobiol 189: 220 – 221Google Scholar
- McRae-Dagueurce A, Booj S, Haglig K, Rosengren L, Karsson JE, Karlsson I, Wallin A, Svennerholm L, Gottfries CG, Dahlström A (1987) Antibodies in the cerebrospinal fluid of some Alzheimer’s disease patients recognize cholinergic neurons in the rat central nervous system. Proc Acad Sci (Wash) 84: 9214 – 9218CrossRefGoogle Scholar
- Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10: 799 – 812Google Scholar
- Thompson RA (1988) Laboratory investigations in clinical immunology: methods, pitfalls and clinical indications. Clin Exp Immunol 74:494–503Google Scholar